25 Aug 2020 Governance

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.

Angela was responsible for driving through the merger with Leuka in November 2019, and is now leaving the charity in a strong position to build on the remarkable transformation she engineered.

She has been a valued Co CEO of the merged charity and a visionary sole CEO of the original charity. We thank her for her outstanding work on our behalf and wish her the very best in the future.

Related posts

The first ever leukaemia-dedicated pathway to improve diagnosis, treatment and care

8 July 2025

The first ever leukaemia-dedicated pathway to improve diagnosis, treatment and care

The Best Practice Timed Pathway We’re delighted to share that Leukaemia UK, in partnership with Lymphoma Action and Myeloma UK, is working with the NHS England Cancer programme team to…

Open letter from cancer charities to the public

18 July 2021

Open letter from cancer charities to the public

40 charities and organisations have written an open letter, urging the public to help keep vulnerable people safe as restrictions ease.

Leukaemia UK’s Patient Care Pioneer Award fuels innovative research to revolutionize ‘watch and wait’ approach

18 November 2024

Leukaemia UK’s Patient Care Pioneer Award fuels innovative research to revolutionize ‘watch and wait’ approach

Leukaemia UK is excited to announce Professor Francesco Forconi from University Hospital Southampton (UHS) as the first recipient of its Patient Care Pioneer Award. Through this new funding initiative, Professor…

A decade on: Dr Javier Redondo Muñoz continues to shape the future of Leukaemia research

18 May 2026

A decade on: Dr Javier Redondo Muñoz continues to shape the future of Leukaemia research

Ten years after joining the second cohort of Leukaemia UK’s John Goldman Fellowships (JGF), Dr Javier Redondo Muñoz is continuing to shape the future of leukaemia research. Now leading his own team in…